At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
Double-Blind 0.2mg CBP-307 +3 moredrug
Likely dose
Double-Blind 0.2mg CBP-307from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
In Brief
A Phase 2 clinical trial evaluating Double-Blind 0.2mg CBP-307, Double-Blind Placebo, and 2 other interventions for Moderate to Severe Ulcerative Colitis. Completed, enrolled 145 participants across 66 sites in 4 countries.
Detailed Summary
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Ulcerative Colitis
CountriesChina, Pakistan, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedJan 2021
Primary CompletionFeb 2022
Study CompletionNov 2022
TodayJul 2026
First PostedJan 7, 2021
Enrollment StartFeb 27, 2019
Primary CompletionFeb 23, 2022
Study CompletionNov 10, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.5 years ago
Interventions
Double-Blind 0.2mg CBP-307drug
0.2 mg capsule oral administration
Double-Blind Placebodrug
Placebo capsule oral administration
Open-label CBP-307drug
0.2 mg capsule oral administration
Double-Blind 0.1mg CBP-307drug
0.1 mg capsule oral administration